$ASMB
Assembly Biosciences, Inc
XNAS
Why is ASMB down today? It is at $33.63 (-1.29%), and our scanner flagged it 40 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment ASMB spikes, and full due diligence on ASMB — key stats, earnings, dilution and insider activity. Free.
Get free $ASMB alerts the moment volume spikes
Our scanner flagged $ASMB 40 times in the last 30 days. Create a free account to track $ASMB, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $33.63
- Change today
- -1.29%
- Previous close
- $34.07
- 52-week range
- $20.23 – $39.70
- Market cap
- $694M
- Total held
- 1.4%
- Tradeable float
- 20.1M 99% of shares · after 1% insiders + institutional n/a
- Short interest
- 2.3M ▼ -1% vs prior · as of 2026-08-14
- Short % of float
- 11.5%
- Days to cover
- 10.1d
- Avg daily volume
- 157K
- Exchange
- XNAS
- 5m
- 0.7x
- 15m
- 0.8x
- 1h
- 0.8x
- 1D
- 0.6x
Get free ASMB + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $ASMB down today?
Here is the latest on ASMB from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for ASMB today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystAssembly Biosciences Reports Second Quarter 2026 Financial Results and Recent UpdatesReported – Completed $115 million gross financing to support advancement of pipeline programs through key development milestones –Reported – Cash runway projected into 2029, including first $75 million Gilead collaboration extension payment due in Q4 2026 –Reported Completed $115 million gross financing expected to extend funding beyond planned ABI-6250 Phase 2 studies in hepatitis delta virus (HDV) and cholestatic liver diseases, from an SEC filing. Read it →Latest filingS-8Employee share plan registration (S-8)Aug 20, 2026 · 11 days agoAnalyst data via Nasdaq. Not investment advice.
Insiders
0 buys, 1 sells last 3 months (11/3 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Bjorkquist Jeanette M Officer | Sold (automatic/other) | -29 | sold 0.2% | 15K | $674 at $23.25 | Jun 17, 26 |
Gilead Sciences, Inc. Beneficial Owner (10%) | Acquired (grant/award) | +472K 2.3% of company | added 10% | 4.98M | $12.5M at $26.50 | May 26, 26 |
Bjorkquist Jeanette M Officer | Sold (automatic/other) | -328 | sold 2.9% | 11K | $9K at $26.65 | Mar 30, 26 |
White Nicole S Officer | Sold (automatic/other) | -197 | sold 0.5% | 37K | $5K at $26.65 | Mar 30, 26 |
Okazaki Jason A Officer | Acquired (grant/award) | +94K 0.5% of company | added 100% | 112K | n/a | Mar 29, 26 |
Delaney William E Iv Officer | Acquired (grant/award) | +26K 0.1% of company | added 100% | 46K | n/a | Mar 29, 26 |
Gaggar Anuj Officer | Acquired (grant/award) | +26K 0.1% of company | added 100% | 28K | n/a | Mar 29, 26 |
White Nicole S Officer | Acquired (grant/award) | +26K 0.1% of company | added 100% | 38K | n/a | Mar 29, 26 |
White Nicole S Officer | Acquired (grant/award) | +14K 0.07% of company | added 41% | 48K | n/a | Mar 29, 26 |
Bjorkquist Jeanette M Officer | Acquired (grant/award) | +7K 0.03% of company | added 100% | 11K | n/a | Mar 29, 26 |
Bjorkquist Jeanette M Officer | Acquired (grant/award) | +4K 0.02% of company | added 32% | 15K | n/a | Mar 29, 26 |
Okazaki Jason A Officer | Acquired (grant/award) | +51K 0.2% of company | added 45% | 163K | n/a | Mar 29, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Active shelfRecent share offering + active shelf on file — the company raised capital and can raise more. If $ASMB runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
- 4,339,642 new shares · Priced at $26.5/share
- About $400.0M in size
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$ASMB Sentiment
BullishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$ASMB Activity
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
ASMB stock FAQ
Why is $ASMB down today?
Here is the latest on ASMB from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for ASMB today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
What is the ASMB stock price today?
ASMB last traded at $33.63, down 1.29% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live ASMB alerts?
The ASMB Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged ASMB 40 times in the last 30 days.
What exchange is ASMB on?
ASMB (Assembly Biosciences, Inc) trades on XNAS, with a market cap of about $694M.
Is ASMB good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge ASMB for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.